



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Rockville, MD 20857

ANDA 090813

Nexus Pharmaceuticals Inc.  
Attention: Shahid Ahmed  
Co-President  
175 E. Hawthorn Parkway, Suite 155  
Vernon Hills, IL 60061

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated October 9, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Levetiracetam Injection, 100 mg/mL, packaged in 500 mg/5 mL Single-use Vials.

Reference is also made to your amendments dated September 17, and November 13, 2009; and January 19, January 26, February 5, February 22, February 24, March 26, and March 31, 2010.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Levetiracetam Injection, 100 mg/mL, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Keppra Injection, 100 mg/mL), of UCB Inc.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

We note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS, See 505-1(i).

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Within 14 days of the date of this letter, submit updated content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling. For administrative purposes, please designate this submission as "**LABELING/SPL FINAL for Approved ANDA 090813**".

Sincerely yours,

*{See appended electronic signature page}*

Keith Webber, Ph.D.  
Deputy Director  
Office of Pharmaceutical Science  
Center for Drug Evaluation and Research

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
----- ANDA-90813	----- ORIG-1	----- NEXUS PHARMACEUTICA LS INC	----- LEVETIRACETAM

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

ROBERT L WEST  
05/26/2010  
Deputy Director, Office of Generic Drugs  
for Keith Webber, Ph.D.